Abstract
Autoimmune disorders, such as systemic lupus erythematosus, are associated with significant morbidity that is often ultimately refractory to current treatment modalities. To target the role of autoantibodies in disease pathogenesis, biologics have been designed for selective targeting of B-cells. However, results have been disappointing as these modalities are unable to deplete long-lived plasma cells that can continue to produce autoreactive antibodies. To target both B-cells and plasma cells, a BCMA-CD19 compound CAR (cCAR) was tested in a patient with 20-year-history of SLE. Despite cessation of immunosuppressant therapy, cCAR alone led to the normalization of complement and antinuclear antibody levels, indicating an effective response to the therapy. This success of cCAR demonstrates that SLE and other antibody-mediated disorders may benefit from dual resetting of both B-cell and plasma cell populations.
Keywords
Antibody-producing cells, B-cells; Plasma cells, BCMA-CD19 CAR, CD19 cCAR, Autoimmune disorders, Systemic lupus erythematosus (SLE)